Cary J Claiborne's Net Worth
$2.12 Million
Who is Cary J Claiborne?
Cary J Claiborne has an estimated net worth of $2.12 Million. This is based on reported shares across multiple companies, which include CYTRX CORP, Sucampo Pharmaceuticals, Inc., OSIRIS THERAPEUTICS, INC., ADIAL PHARMACEUTICALS, INC., and New Generation Biofuels Holdings, Inc.
SEC CIK
Cary J Claiborne's CIK is 0001370930
Past Insider Trading and Trends
2009 was Cary J Claiborne's most active year for acquiring shares with 20 total transactions. Cary J Claiborne's most active month to acquire stocks was the month of November. 2013 was Cary J Claiborne's most active year for disposing of shares, totalling 10 transactions. Cary J Claiborne's most active month to dispose stocks was the month of October. 2007 saw Cary J Claiborne paying a total of $478,400.00 for 335,000 shares, this is the most they've acquired in one year. In 2014 Cary J Claiborne cashed out on 110,000 shares for a total of $690,364.60, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
CYTRX CORP (LADX) Snapshot price: $1.5
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Sucampo Pharmaceuticals, Inc. No price found
Chief Financial OfficerCary J Claiborne owns 2,621 units of Common Stock (ESPP), 2,864 units of Class A Common Stock, 1,685 units of Class A Common Stock (ESPP). Cary J Claiborne used to own units in Common Stock but no longer holds any shares there. In the year 2011 Cary J Claiborne filed a total of 19 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$8.49 | -$441,858.00 | 2.86K |
Dec 15 - Dec 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 11
| |||
Form 4
| +11.34% | 267 |
$6.56 | $1,751.52 | 2.62K |
Jun 30
| |||
Form 4
| +10.31% | 220 |
$6.79 | $1,493.80 | 2.35K |
Mar 31
| |||
Form 4
|
—
|
0
|
$6.54 | -$12,331.60 |
0
|
Scheduled
|
Feb 27
| ||
Form 4
|
—
|
0
|
$6.70 | -$11,509.00 |
0
|
Scheduled
|
Jan 7
| ||
Form 4
| +10.11% | 196 |
$8.93 | $1,750.28 | 2.13K |
Dec 31
| |||
Form 4
| -13.05% | -16.50K |
$7.60 | -$125,428.02 | 109.9K |
Nov 22 - Nov 25
| |||
Form 4
| +15.01% | 253 |
$5.93 | $1,499.78 | 1.94K |
Sep 30
| |||
Form 4/A
| +19.93% | 280 |
$6.25 | $1,750.28 | 1.69K |
Jun 28
| |||
Form 4
| -7.56% | -10.30K |
$9.00 | -$92,735.02 | 125.86K |
May 24
| |||
Form 4
| -3.30% | -4.64K |
$9.52 | -$44,194.00 | 136.16K |
May 20 - May 21
| |||
Form 4
| +20.81% | 242 |
$6.21 | $1,503.55 | 1.41K |
Mar 28
| |||
Form 4
| +47.78% | 376 |
$4.66 | $1,750.28 | 1.16K |
Dec 31
| |||
Form 4
| +66.03% | 313 |
$4.78 | $1,495.67 | 787 |
Sep 28
| |||
Form 4
| +124.64% | 263 |
$6.68 | $1,756.45 | 474 |
Jun 29
| |||
Form 4
|
∞
| 211 |
$7.08 | $1,493.35 | 211 |
Mar 30
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
OSIRIS THERAPEUTICS, INC. No price found
Chief Financial OfficerCary J Claiborne owns 75,000 units of Common Stock. In the year 2006 Cary J Claiborne filed a total of 5 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 23
| |||
Form 4
| +25.00% | 15K |
$0.40 | $6,000.00 | 75K |
Mar 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 5
| |||
Form 4
| +300.00% | 45K |
$0.40 | $18,000.00 | 60K |
Sep 27
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
ADIAL PHARMACEUTICALS, INC. (ADIL) Snapshot price: $0.99
Chief Executive OfficerCary J Claiborne owns 1,520,000 units of Common Stock which is worth $1,504,800.00. From 2021 to 2024 Cary J Claiborne acquired a total of 1,520,000 shares in ADIAL PHARMACEUTICALS, INC. at a cost of $42,250.00.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 25
| |||
Form 4
| +38.18% | 420K |
—
|
—
| 1.52M |
May 23
| |||
Form 4
| +10.00% | 100K |
$0.42 | $42,250.00 | 1.1M |
Sep 19 - Sep 20
| |||
Form 4
|
∞
| 1M |
—
|
—
| 1M |
Aug 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 7
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
New Generation Biofuels Holdings, Inc No price found
CEO, CFO and PresidentCary J Claiborne owns 284,979 units of Common Stock. In the year 2009 Cary J Claiborne filed a total of 12 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +7.55% | 20K |
$0.71 | $14,186.00 | 284.98K |
Dec 24 - Dec 28
| |||
Form 4
| +8.16% | 20K |
$0.70 | $13,981.38 | 264.98K |
Dec 18 - Dec 21
| |||
Form 4
| +13.46% | 29.07K |
—
|
—
| 244.98K |
Dec 1
| |||
Form 4
| +16.56% | 30.67K |
—
|
—
| 215.91K |
Mar 18 - Aug 7
| |||
Form 4/A
| +18.97% | 29.53K |
—
|
—
| 185.24K |
Jun 10
| |||
Form 4/A
| +341.89% | 120.47K |
—
|
—
| 155.71K |
May 27
| |||
Form 4
| +83.60% | 29.53K |
—
|
—
| 64.86K |
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 27
| |||
Form 4
| +244.24% | 25K |
—
|
—
| 35.24K |
Dec 1
| |||
Form 4
| +41.19% | 2.99K |
—
|
—
| 10.24K |
Mar 5 - May 12
| |||
Form 4
| +625.00% | 6.25K |
—
|
—
| 7.25K |
Dec 1 - Jan 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||